Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Diagnostic utility of the risk of malignancy index for borderline ovarian tumors
So Ra Oh1, Jung-Woo Park1, *
1 Department of Obstetrics and Gynecology, Dong-A University Medical Center, Dong-A University, College of Medicine, Busan, Republic of Korea
Eur. J. Gynaecol. Oncol. 2018, 39(3), 437–442; https://doi.org/10.12892/ejgo4006.2018
Published: 10 June 2018
Purpose of investigation: To determine the best cutoff value for the risk of malignancy index (RMI) by comparing the four malignancy risk indices (RMI 1, RMI 2, RMI 3, and RMI 4) in patients with borderline ovarian tumors (BOTs). Materials and Methods: The authors enrolled 510 patients in this retrospective study: 76 women with BOTs and 434 with benign adnexal masses. There were no restrictions in BOT histotypes. Results: The area under the curves for RMI 1, RMI 2, RMI 3, and RMI 4 were 0.742, 0.755, 0.765, and 0.787, respectively. RMI 4 performed better in diagnosing BOT preoperatively than RMI 1, RMI 2, and RMI 3, at a cutoff value of 190. Conclusion: RMI 4 at a cutoff value of 190 can be successfully used for identifying patients with suspected BOTs who require specialist referral.
Borderline ovarian tumor
Risk of malignancy index